The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

Ronnie Uhlmann is afflicted with branch retinal vein occlusion, which, her husband Peter, a retired physician said, means the ...

Treatment with high dose aflibercept 8 mg can lead to similar visual outcomes with fewer injections for patients with RVO.

ABSTRACT: Aim: This study aims to present a rare case of branch retinal vein occlusion (BRVO) that developed after cataract surgery and to evaluate possible preoperative and intraoperative risk ...

ABSTRACT: Aim: This study aims to present a rare case of branch retinal vein occlusion (BRVO) that developed after cataract surgery and to evaluate possible preoperative and intraoperative risk ...

Patients with obstructive sleep apnea had an elevated risk for branch retinal vein occlusion, highlighting the potential need for routine ophthalmologic screening in this population. Risk for retinal ...